SeaStar Medical (ICU) vs NewcelX (NCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
SeaStar Medical (ICU) has outperformed NewcelX (NCEL) over the past year, losing 47.0% versus a loss of 83.3%. Over five years, NCEL leads with a -99.7% price change compared with -99.9% for ICU. SeaStar Medical is the larger company by market cap ($18.4 million vs $18.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ICU | NCEL |
|---|---|---|
| Share price | $3.49 | $3.11 |
| Market cap | $18.36M | $17.96M |
| 1-day change | -6.18% | +2.47% |
| YTD return | +45.42% | +63.68% |
| 1-year return | -47.04% | -83.32% |
| 5-year return | -99.86% | -99.68% |
| P/E ratio (TTM) | — | 5.98 |
| EPS (TTM) | $-2.97 | $0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.35 | $18.60 |
| 52-week low | $2.07 | $1.83 |
| Distance from 52-week high | -52.52% | -83.28% |
| Analyst consensus | none | none |
| Avg. price target upside | +186.53% | +639.55% |
| Average volume | 99.80K | 10.28K |
| Shares outstanding | 5.26M | 5.78M |
| Employees | 18 | 9 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ICU has outperformed NCEL by 36.3 percentage points over the past year.
About SeaStar Medical
ICU stock →SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis.
Healthcare · Biotechnology · 18 employees
About NewcelX
NCEL stock →NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders.
Healthcare · Biotechnology · 9 employees
ICU vs NCEL FAQ
Which is bigger, SeaStar Medical or NewcelX?
SeaStar Medical (ICU) is larger, with a market capitalization of $18.36M compared with $17.96M for NewcelX (NCEL).
Which stock has performed better over the past year, ICU or NCEL?
ICU returned -47.04% over the past 12 months, compared with -83.32% for NCEL (price return, excluding dividends). Past performance does not predict future results.
Are SeaStar Medical and NewcelX in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.